Oncomed Pharmaceuticals Inc (OMED) 22.56 $OMED
How This 1 Company Is Attempting to Overcome One of Cancer's Greatest Risk Factors
Sean Williams, The Motley Fool - Motley Fool - Sat May 10, 1:05PM CDT
Cancer is one of the scariest disease diagnoses imaginable, at least according to one U.K. study , and that's primarily because researchers, despite decades of work and collaboration, are still scratching the surface on what triggers cancer in the...
OncoMed Pharmaceuticals Announces First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 8:31AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported financial results and reviewed corporate events for the quarter ended March 31, 2014.
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
OncoMed awarded orphan drug designation for Demcizumab for treating pancreatic cancer
M2 - Mon May 05, 7:32AM CDT
Novel therapeutics developer OncoMed Pharmaceuticals (NasdaqGS:OMED) reported on Friday the receipt of orphan drug designation for demcizumab (anti-DLL4, OMP-21M18) for the treatment of pancreatic cancer from the US Food and Drug Administration's (FDA) Department of Orphan Products Development.
OncoMed Receives Orphan Drug Designation From the FDA for Demcizumab in Pancreatic Cancer
GlobeNewswire - Fri May 02, 7:34AM CDT
OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the U.S. Food and Drug Administration (FDA) Department of Orphan Products Development has granted orphan drug designation to demcizumab (anti-DLL4, OMP-21M18) for the treatment of pancreatic cancer. OncoMed is currently conducting a Phase 1b clinical trial of demcizumab in combination with Abraxane (nab-paclitaxel) and gemcitabine in first-line Stage IV pancreatic cancer patients.
Celgene Earnings Grow Year Over Year in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:27PM CDT
Product sales increased at Celgene (CELG) in the quarter.
OncoMed Announces Abstracts Accepted at the 2014 ASCO Annual Meeting
GlobeNewswire - Wed Apr 23, 7:30AM CDT
OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that several abstracts have been accepted for presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2014 in Chicago, IL.
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gctlqw/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Adherex Technologies Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - FibroGen, Inc. - Novartis AG - Pfizer Inc. - Celgene Corporation - Bayer AG - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Insys Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - AB Science - Oncovir, Inc. - ParinGenix, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. Drug Profiles - paclitaxel albumin-bound - irinotecan sucrosofate liposomal - masitinib - cisplatin liposomal - cisplatin - refametinib - selumetinib sulfate - trametinib dimethyl sulfoxide - docetaxel - paclitaxel albumin-bound - ganetespib - RX-0201 - irinotecan sucrosofate liposomal - PGX-100 - lurbinectedin - yttrium Y 90 clivatuzumab tetraxetan - Cancer Inhibitor Macrobeads - TL-118 - LY-2090314 - hydroxychloroquine - LY-2495655 - PEGPH-20 - M-402 - pentamidine isethionate - veliparib - galunisertib - ADH-1 - FG-3019 - demcizumab - LCL-161 For more information visit http://www.researchandmarkets.com/research/gctlqw/metastatic
Falling Earnings Estimates Signal Weakness Ahead for OncoMed Pharmaceuticals (OMED) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 7:43AM CDT
OncoMed Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting
GlobeNewswire - Tue Apr 08, 8:39AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced data from an oral presentation and eight poster presentations at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, CA April 5-9, 2014. The research presented at AACR highlight OncoMed's drug discovery platforms along with preclinical and biomarker discoveries on its clinical-stage product candidates and several emerging product candidates. A brief summary of each presentation is provided below.
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 04, 5:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
PR Newswire - Tue Mar 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Adams Street Partners Venture Funds Achieve Three IPOs in Consecutive Days
Business Wire - Mon Mar 24, 3:04PM CDT
Adams Street Partners, LLC ("ASP"
, a global private equity firm, announced today that three of its portfolio companies launched IPOs in successive days last week. The three companies represent investments made by Adams Street Partners' direct venture capital and growth equity team.
OncoMed's Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:50PM CDT
OncoMed reported a loss of 15 cents per share, narrower than the year-ago loss of $4.01 per share but missing the Zacks Consensus Estimate earnings of 4 cents per share.
OncoMed Pharmaceuticals Announces Full Year and Fourth Quarter 2013 Financial Results
GlobeNewswire - Tue Mar 18, 7:43AM CDT
Year-End Cash and Cash Equivalents Balance of $316.2 Million Reflecting IPO and Celgene Multi-Product Co-Development Collaboration
How This 1 Company Is Attempting to Overcome One of Cancer's Greatest Risk Factors
Sean Williams, The Motley Fool - Motley Fool - Sat May 10, 1:05PM CDT
Cancer is one of the scariest disease diagnoses imaginable, at least according to one U.K. study , and that's primarily because researchers, despite decades of work and collaboration, are still scratching the surface on what triggers cancer in the...
OncoMed Pharmaceuticals Announces First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 8:31AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported financial results and reviewed corporate events for the quarter ended March 31, 2014.
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
OncoMed awarded orphan drug designation for Demcizumab for treating pancreatic cancer
M2 - Mon May 05, 7:32AM CDT
Novel therapeutics developer OncoMed Pharmaceuticals (NasdaqGS:OMED) reported on Friday the receipt of orphan drug designation for demcizumab (anti-DLL4, OMP-21M18) for the treatment of pancreatic cancer from the US Food and Drug Administration's (FDA) Department of Orphan Products Development.
OncoMed Receives Orphan Drug Designation From the FDA for Demcizumab in Pancreatic Cancer
GlobeNewswire - Fri May 02, 7:34AM CDT
OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the U.S. Food and Drug Administration (FDA) Department of Orphan Products Development has granted orphan drug designation to demcizumab (anti-DLL4, OMP-21M18) for the treatment of pancreatic cancer. OncoMed is currently conducting a Phase 1b clinical trial of demcizumab in combination with Abraxane (nab-paclitaxel) and gemcitabine in first-line Stage IV pancreatic cancer patients.
Celgene Earnings Grow Year Over Year in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:27PM CDT
Product sales increased at Celgene (CELG) in the quarter.
OncoMed Announces Abstracts Accepted at the 2014 ASCO Annual Meeting
GlobeNewswire - Wed Apr 23, 7:30AM CDT
OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that several abstracts have been accepted for presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2014 in Chicago, IL.
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gctlqw/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Adherex Technologies Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - FibroGen, Inc. - Novartis AG - Pfizer Inc. - Celgene Corporation - Bayer AG - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Insys Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - AB Science - Oncovir, Inc. - ParinGenix, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. Drug Profiles - paclitaxel albumin-bound - irinotecan sucrosofate liposomal - masitinib - cisplatin liposomal - cisplatin - refametinib - selumetinib sulfate - trametinib dimethyl sulfoxide - docetaxel - paclitaxel albumin-bound - ganetespib - RX-0201 - irinotecan sucrosofate liposomal - PGX-100 - lurbinectedin - yttrium Y 90 clivatuzumab tetraxetan - Cancer Inhibitor Macrobeads - TL-118 - LY-2090314 - hydroxychloroquine - LY-2495655 - PEGPH-20 - M-402 - pentamidine isethionate - veliparib - galunisertib - ADH-1 - FG-3019 - demcizumab - LCL-161 For more information visit http://www.researchandmarkets.com/research/gctlqw/metastatic
Falling Earnings Estimates Signal Weakness Ahead for OncoMed Pharmaceuticals (OMED) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 7:43AM CDT
OncoMed Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting
GlobeNewswire - Tue Apr 08, 8:39AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced data from an oral presentation and eight poster presentations at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, CA April 5-9, 2014. The research presented at AACR highlight OncoMed's drug discovery platforms along with preclinical and biomarker discoveries on its clinical-stage product candidates and several emerging product candidates. A brief summary of each presentation is provided below.
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 04, 5:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
PR Newswire - Tue Mar 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Adams Street Partners Venture Funds Achieve Three IPOs in Consecutive Days
Business Wire - Mon Mar 24, 3:04PM CDT
Adams Street Partners, LLC ("ASP"
, a global private equity firm, announced today that three of its portfolio companies launched IPOs in successive days last week. The three companies represent investments made by Adams Street Partners' direct venture capital and growth equity team. OncoMed's Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:50PM CDT
OncoMed reported a loss of 15 cents per share, narrower than the year-ago loss of $4.01 per share but missing the Zacks Consensus Estimate earnings of 4 cents per share.
OncoMed Pharmaceuticals Announces Full Year and Fourth Quarter 2013 Financial Results
GlobeNewswire - Tue Mar 18, 7:43AM CDT
Year-End Cash and Cash Equivalents Balance of $316.2 Million Reflecting IPO and Celgene Multi-Product Co-Development Collaboration
